Abatacept demonstrated efficacy among patients with steroid-refractory chronic graft-versus-host-disease, according to phase 2 study results.
Use of the agent led to durable reductions in prednisone dosing, findings presented at Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR showed.
Abatacept (Orencia, Bristol Myers Squibb) — a recombinant fusion protein — is comprised of the extracellular domain of CTLA-4, linked to the modified Fc portion of human immunoglobulin G1 that binds to CD80 and CD86 on antigen-presenting cells, according to study